See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/26296023

ChemInform Abstract: Concise Synthesis of Iminocyclitols via Petasis-Type Aminocyclization

ARTICLE in LOURNAL	OF THE AMERICAN CHEMICAL	SOCIFTY .	IIII Y 2000

Impact Factor: 12.11 · DOI: 10.1021/ja901656e · Source: PubMed

CITATIONS READS 17

5 AUTHORS, INCLUDING:



Zhangyong Hong

Nankai University

30 PUBLICATIONS 397 CITATIONS

SEE PROFILE



Masakazu Sugiyama

AJINOMOTO CO., INC.

26 PUBLICATIONS 638 CITATIONS

SEE PROFILE



Am Chem Soc. Author manuscript; available in PMC 2010 July 8.

Published in final edited form as:

J Am Chem Soc. 2009 June 24; 131(24): 8352–8353. doi:10.1021/ja901656e.

Concise Synthesis of Iminocyclitols via Petasis-type Aminocyclization

Zhangyong Hong, Lei Liu, Masakazu Sugiyama, Yu Fu, and Chi-Huey Wong
Department of Chemistry and the Skaggs Institute for Chemical Biology, The Scripps Research
Institute, 10550 North Torrey Pines Rd., La Jolla, CA 92037

Iminocyclitols are metabolically inert carbohydrates mimicking the oxocarbenium ion-like transition state of carbohydrate-processing enzymes. Many iminocyclitols exhibit strong binding to glycosidases and glycotransferases. Accordingly they have been intensively evaluated for antivirial, anticancer, and antidiabetic properties. Some of them have already achieved market success, such as Miglitol for treatment of noninsulin-dependent diabetes. Further biopharmaceutical studies on iminocyclitols are warranted. However, a significant challenge that remains to be overcome is the demand for a cost-effective method to make iminocyclitols. Currently most iminocyclitol syntheses involve the introduction of an amino function in the sugar skeleton, followed by aminocyclization to generate the piperidine or pyrrolidine ring through reductive amination. These syntheses often require lengthy protection/deprotection steps and are tedious and low-yielding. An additional problem often encountered is the low diastereoselectivity in reductive amination.

Here we report a novel, concise approach to iminocyclitols that exploits an unprecedented synthetic strategy to build piperidine and pyrrolidine rings with high stereocontrol via Petasistype three-component condensation. The advantage of the Petasis boronic acid-Mannich reaction⁴ is that chiral compounds can be efficiently produced in a single process with minimum protecting group manipulation. Accessibility of the reagents and the mild reaction conditions also make the method extremely practical. Previously we developed a three-step route to sialic acids and analogs by using the Petasis reaction.⁵ We now demonstrate for the first time that Petasis reaction can be used to synthesize several types of biologically important iminocyclitols.

As a representative example, the new synthesis is detailed in Scheme 1 for the preparation of iminocyclitol $\bf 3a$. The starting material is a polyhydroxyl dialdehyde that can be readily prepared from the corresponding commercially available monosaccharide, i.e., 3,4-O-isopropylidene-D-mannitol ($\bf 1a$). To avoid the use of toxic Pb-containing reagents, we tested and found that PhI(OAc)₂ can quantitatively oxidize $\bf 1a$ to a dialdehyde at room temperature. Addition of 0.1 M $\bf H_2SO_4$ to the reaction mixture removes the acetone protecting group. Subsequently NH₃ and styrylboronic acid are added to the aqueous reaction mixture, resulting in twice Petasis-type condensations. The final product of the above one-pot reaction sequence is compound $\bf 2a$ (de > 98%) in 70% isolated yield from $\bf 1a$.

Some unusual observations are worth noting for the above Petasis-type condensation. First, according to the previous studies on Petasis-type condensation, compound **3a** is not the "expected" diastereomer (Note: the "expected" product cannot be observed even in trace

wong@scripps.edu.

amount in our experiment). Second, the condensation in Scheme 1 surprisingly presents the *first* example for the use of ammonia in Petasis boronic acid-Mannich condensation. In fact, our experiments with D-arabinose clearly show that although benzylamine can readily condense with this saccharide, ammonia cannot do so (Scheme 2). On the other hand, both benzylamine and ammonia can condense with the dialdehyde generated *in situ* from 3,4-*O*-isopropylidene-D-mannitol.

To interpret the observations we suggest that the above reaction proceed *via* an unprecedented intermediate. As shown in Scheme 3, it is proposed that the dialdehyde intermediate may form a five-membered imininum ion **i** or its isomer with ammonia (both isomers will lead to the same final product). Reversible coordination of styrylboronic acid with an OH group promotes *cis*-addition of the vinyl group to the C=N double bond. This step produces a new five-membered iminium ion **ii** that may undergo *cis*-vinylation producing compound **2a**. The mechanism explains that the *cis*, but not the *trans* product is observed in the condensation. The favored formation of a five-membered ring also explains that NH₃ (which is not likely to form imines) may participate in this particular reaction.

Ozonolysis of 2a may yield 3a in theory (Scheme 1). However, by using the standard ozonolysis/reduction procedure we only obtain some unidentified byproducts. It is hypothesized that the free amino group in 2a interferes with ozonolysis. To test this speculation, 2a is protected with $(Boc)_2O$ and the corresponding carbamate is subjected to ozonolysis and $NaBH_4$ reduction. After TFA treatment, compound 3a is obtained successfully in 60% yield. To improve the synthesis we next seek to use proton to protect the amino group in 2a. After examinations with a number of acids, we are delighted to find that by adding $HClO_4$ to the MeOH solution of 2a we can cleanly ozonolyze 2a and then reduce it with $NaBH_4$ to 3a in 85% yield.

At this point we accomplish the synthesis of **3a** from a readily available starting material (i.e. **1a**) in only two steps. Both steps can be readily carried out under mild conditions. The overall yield is 60% (Table 1, entry 1) and the synthesis can be easily scaled up. Previously **3a** was synthesized from PMP-protected ethyl 4-hydroxybut-2-enoate in eight steps with an overall yield of 8%. By using the same procedure, the enantiomer of **3a** (i.e. **3b**) is synthesized from 3,4-O-isopropylidene-L-mannitol (entry 2). As a strong inhibitor of α -fucosidase, **3b** was recently synthesized in seven steps from tri-O-benzyl-D-glucal with an overall yield of 38%. Furthermore, from readily available cis-3,4-dihydroxy-2,5-dimethoxy tetrahydrofuran, we generate the dialdehyde by using 0.1 M H₂SO₄ and then conduct Petasis-type condensation with NH₃. Ozonolysis/reduction of the intermediate produces **3c** with an overall yield of 52%. As a strong inhibitor of α -galactosidase, **8 3c** was previously synthesized chemoenzymatically from dihydroxyacetone phosphate and 2-azido-3-hydroxypropanal in three steps by using fructose-1-phosphate aldolase. Representations of the intermediate produces are the steps by using fructose-1-phosphate aldolase.

The above synthetic route can also be used to prepare six-membered iminocyclitols (entries 4-7). The starting materials for the syntheses are 1,2 or 2,3-O-isopropylidene-protected D-glucose, D-mannose,9 D-galactose, 10 and D-allose, which are either commercially available or readily synthesized. The same one-pot reaction sequence of PhI(OAc) $_2$ oxidation, H $_2$ SO $_4$ deprotection, and Petasis condensation provides the bis-vinylated intermediates, which are ozonolyzed to iminocyclitols 3d- $3g^{11,12}$ with an overall yield of ca. 50%.

To conclude, a two-step method has been developed to synthesize several biologically important iminocyclitols in *ca.* 50-60% yields by using Petasis-type condensation. The methods is very general and operationally simple, affording a series of iminocyclitols from easily available sugar derivatives. Unexpected diastereoselectivities are observed, suggesting

that the condensation may proceed through an unprecedented five- or six-membered cyclic iminium ion intermediate.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank the National Institutes of Health for the financial support.

References

- Recent reviews: a Asano N, Nash RJ, Molyneux RJ, Fleet GWJ. Tetrahedron: Asymmetry 2000;11:1645. b Lillelund VH, Jensen HH, Liang X, Bols M. Chem. Rev 2002;102:515. [PubMed: 11841253] c Ayad T, Genisson Y, Baltas M. Curr. Org. Chem 2004;8:1211. d Whalen LJ, Wong C-H. Aldrichim. Acta 2006;39:63.
- a Winchester B, Fleet GWJ. Glycobiology 1992;2:199. [PubMed: 1498417] b Sears P, Wong C-H. Angew. Chem., Int. Ed 1999;38:2300. c Ouchi H, Mihara Y, Takahata H. J. Org. Chem 2005;70:5207. [PubMed: 15960525] d Liang P-H, Cheng W-C, Lee Y-L, Yu H-P, Wu Y-T, Lin Y-L, Wong C-H. ChemBioChem 2006;7:165. [PubMed: 16397876]
- 3. Sugiyama M, Hong Z, Liang P-H, Dean SM, Whalen LJ, Wong C-H. J. Am. Chem. Soc 2007;129:14811. [PubMed: 17985886]
- a Petasis NA, Zavialov IA. J. Am. Chem. Soc 1997;119:445. b Petasis NA, Zavialov IA. J. Am. Chem. Soc 1998;120:11798.
- 5. Hong Z, Liu L, Hsu C-C, Wong C-H. Angew. Chem. Int. Ed 2006;45:7417.
- 6. Singh S, Han H. Tetrahedron Lett 2004;45:6349.
- 7. a umar V, Ramesh N. Tetrahedron 2006;62:1877. b Takayama S, Martin R, Wu J, Laslo K, Siuzdak G, Wong C-H. J. Am. Chem. Soc 1997;119:8146. and references cited therein.
- 8. a Wang Y-F, Takaoka Y, Wong C-H. Angew. Chem. Int. Ed 1994;33:1242. b Fechter MH, Stutz AE. Carbohydr. Res 1999;319:55.
- 9. Nygaard M R, Madsen R. J. Org. Chem 2007;72:9782. [PubMed: 17979290]
- 10. Morgenlie S. Acta Chem. Scand 1973;27:3609.
- 11. Previously **3d** and **3e** were prepared from 2,3,4,6-tetra-O-benzyl-D-glucopyranoses and mannopyranoses in six steps with overall yields of 12% and 3.8%. a Dondoni A, Nuzzi A. J. Org. Chem 2006;71:7574. [PubMed: 16995661]; b Liu T, Zhang Y, Bleriot Y. Synlett 2007:905.
- 12. **3f** was previously prepared from tetra-O-benzyl-D-galactopyranose in seven steps with an overall yield of 17%. Ye X-S, Sun F, Liu M, Li Q, Wang Y, Zhang G, Zhang L-H, Zhang X-L. J. Med. Chem 2005;48:3688. [PubMed: 15916418] As a natural product, **3f** is a very potent inhibitor of α-galactosidase and human lysosomal galactosidase A. a Asano N, Nishida M, Kizu H, Matsui K, Watson AA, Nash RJ. J. Nat. Prod 1997;60:98.; b Shilvock JP, Nash RJ, Watson AA, Winters AL, Butters TD, Dwek RA, Winkler DA, Fleet GW. J. Chem. Soc. Perkin Trans. 1 1999:2747.; c Martin OR, Savedra OM, Xie F, Liu L, Picasso S, Vogel P, Kizu H, Asano N. Bioorg. Med. Chem 2001;9:1269. [PubMed: 11377185]


Scheme 1.

Scheme 2.

Scheme 3.

Table 1

Two-step synthesis of iminocyclitols.



1a

2

Hong et al. Page 8

Entry Starting material

1b

MeO OME

HO OH

1c

 $\begin{array}{c|c} & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ & \\ &$

Entry Starting material